ArticleCancers2022
A Comparison between Patient- and Physician-Reported Late Radiation Toxicity in Long-Term Prostate Cancer Survivors.
Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 12 citations in OpenAlex.
- Post-prostatectomy magnetic resonance-guided adaptive salvage radiotherapy: early toxicity and biochemical outcomes from a prospective single center cohort.Clinical and translational radiation oncology · 2026Article
- Acute toxicity and patient-reported quality of life during daily online adaptive radiotherapy versus conventional IGRT for localized prostate cancer: a prospective parallel cohort study.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Temporary prostate brachytherapy alone or as boost: Single-institution experience on dose-response assessment focusing on sphincter-related urinary toxicity.Journal of contemporary brachytherapy · 2026Article
- Prospective evaluation of acute side effects profiles in moderately hypofractionated whole-pelvic radiotherapy for prostate cancer.Clinical and translational radiation oncology · 2026Article
- Toxicity of rectal preparation strategies in ultra-hypofractionated SBRT for prostate cancer.Technical innovations & patient support in radiation oncology · 2026Article
- Factors Associated With Rectal Spacer Use in Prostate Cancer Patients Receiving Radiation Therapy.Cancer medicine · 2026Article
- Predictors of acute genitourinary toxicity in real-time image-gated spot-scanning proton beam therapy for prostate cancer.Journal of radiation research · 2026Article
- Developing evidence-based, cost-effective P4 cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities.Molecular oncology · 2026Article
- Towards Personalized Radiotherapy in Pelvic Cancer: Patient-Related Risk Factors for Late Radiation Toxicity.Current oncology (Toronto, Ont.) · 2025Review
- Genetic markers of late radiation toxicity in the era of image-guided radiotherapy: lower toxicity rates reduce the predictive value of γ-H2AX foci decay ratio in patients undergoing pelvic radiotherapy.Radiation oncology (London, England) · 2024Article
- Article
- Evaluation of Relationship between Intrinsic Radiosensitivity (Survival Fraction at 2 Gy) and Gamma-H2AX Test and Apoptosis of Lymphocytes in Breast Cancer Patients.Journal of medical signals and sensors · 2024Article
- The Association between Acute and Late Genitourinary and Gastrointestinal Toxicities: An Analysis of the PACE B Study.Cancers · 2023Article
- Predictive modelling for late rectal and urinary toxicities after prostate radiotherapy using planned and delivered dose.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Patient-reported outcome measures (PROMs) are advocated for the monitoring of toxicity after radiotherapy. However, studies comparing physician- and patient-reported toxicity show low concordance. In this study, we compared physician- and patient-reported toxicity in long-term prostate cancer survivors after radiotherapy, and we determined the correlation with a presumable risk factor for late toxicity: γ-H2AX foci decay ratio (FDR). Patients formerly included in a prospective study were invited to participate in this new study, comprising one questionnaire and one call with a trial physician assistant. Concordance was calculated for seven symptoms. Gamma-H2AX FDRs were determined in ex vivo irradiated lymphocytes in a previous analysis. Associations between FDR and long-term prevalence of toxicity were assessed using univariable logistic regression analyses. The 101 participants had a median follow-up period of 9 years. Outcomes were discordant in 71% of symptomatic patients; in 21%, the physician-assessed toxicity (using CTCAE) was higher, and, in 50%, the patients reported higher toxicity. We did not find a correlation between presence of toxicity at long-term follow-up and FDR. In conclusion, patients assigned greater severity to symptoms than the trial physician assistant did. Consideration of both perspectives may be warranted to provide the best care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.